Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of the study is to compare overall survival (OS) in subjects treated with lenvatinib versus sorafenib as a first-line treatment in subjects with unresectable heptocellular carcinoma (HCC)
Critère d'inclusion
- Unresectable Hepatocellular Carcinoma